Related references
Note: Only part of the references are listed.Rebound activity after fingolimod cessation: A case - control study
Andres Barboza et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)
Therapy Switches in Fingolimod-Treated Patients with Multiple Sclerosis: Long-Term Experience from the German MS Registry
Niklas Frahm et al.
NEUROLOGY AND THERAPY (2022)
Multiple Sclerosis Relapses Following Cessation of Fingolimod
Charles B. Malpas et al.
CLINICAL DRUG INVESTIGATION (2022)
Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series
Silvia Delgado et al.
BMC NEUROLOGY (2021)
Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab
Steffen Pfeuffer et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2021)
Challenges of switching towards anti-CD20 monoclonal antibodies in RR-MS: A monocentric study
Marine Boudot de la Motte et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)
Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation
Tiina Mustonen et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Severe fingolimod rebound syndrome after switching to cladribine treatment
Fernanda Coss-Rovirosa et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe
Carmen Alcala et al.
JOURNAL OF NEUROLOGY (2019)
Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations
Brian Barry et al.
NEUROLOGY AND THERAPY (2019)
Unexpected high multiple sclerosis activity after switching from fingolimod to alemtuzumab
Raphael Bernard-Valnet et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2018)
Fingolimod alters the transcriptome profile of circulating CD4+cells in multiple sclerosis
Joerg Friess et al.
SCIENTIFIC REPORTS (2017)
Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment
Stacy Ellen Hatcher et al.
JAMA NEUROLOGY (2016)
Rebound of Disease Activity After Withdrawal of Fingolimod (FTY720) Treatment
Joachim B. Havla et al.
ARCHIVES OF NEUROLOGY (2012)